Mynewsdesk LinkedIn

The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibodys latest Press releases

To the archive

2022-01-12

Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics

Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered...[read more]

2021-12-14

Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from...[read more]

2021-12-09

Phase 2 HER2-targeting Study Presented at SABCS...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies